Inter Partes Review: Patent Killer No More?

完整後設資料紀錄

DC 欄位	值	語言
dc.contributor.author	Chen, Feng-Chi	en_US
dc.contributor.author	Lee, Pin-Shen	en_US
dc.date.accessioned	2019-08-02T02:18:29Z	-
dc.date.available	2019-08-02T02:18:29Z	-
dc.date.issued	2019-07-01	en_US
dc.identifier.issn	0167-7799	en_US
dc.identifier.uri	http://dx.doi.org/10.1016/j.tibtech.2019.02.006	en_US
dc.identifier.uri	http://hdl.handle.net/11536/152312	-
dc.description.abstract	Inter Partes review (IPR) can efficiently invalidate drug patents and potentially convey strategic advantages to follow-on drug makers. However, recent changes in the IPR system foretell a tectonic shift in the landscape. Here we summarize these major changes and discuss the implications for the biopharmaceutical community.	en_US
dc.language.iso	en_US	en_US
dc.title	Inter Partes Review: Patent Killer No More?	en_US
dc.type	Article	en_US
dc.identifier.doi	10.1016/j.tibtech.2019.02.006	en_US
dc.identifier.journal	TRENDS IN BIOTECHNOLOGY	en_US
dc.citation.volume	37	en_US
dc.citation.issue	7	en_US
dc.citation.spage	680	en_US
dc.citation.epage	683	en_US
dc.contributor.department	科技法律學院	zh_TW
dc.contributor.department	College of Law	en_US
dc.identifier.wosnumber	WOS:000471155300002	en_US
dc.citation.woscount	0	en_US
顯示於類別：	期刊論文